CABS upcoming events

CABS 2026 Data Science Summer Intern Program – Now Accepting Applications (January 01, 2026)

Thu, 01 Jan 2026 08:00:00 GMT

The Chinese American Biopharmaceutical Society (CABS) is pleased to announce the 2026 Data Science Summer Intern Program, a 10-week remote internship designed to train the next generation of data science leaders in the U.S. biopharma industry.

Open to undergraduate, master’s, and Ph.D. students currently studying in the United States, this program offers hands-on experience applying AI, machine learning, and data analytics to real-world challenges across the drug development process — from target discovery to clinical research and commercialization.

Interns will collaborate with data science teams from CABS member companies, attend professional workshops, and receive mentorship from industry experts.

Timeline

Applications Open: January 1, 2025
Deadline: May 15, 2026
Internship Dates: June 15 – August 15, 2026

This is a non-paid, remote, educational internship — CPT is not required.

Contact Dr. Shicheng Guo (shicheng.guo@cabsweb.org) for more details.

Registration Page: https://forms.gle/kfKVcw9N1ptJLaoj6

2026 BioPacific Conference Sponsor and Exhibitor Payment (May 01, 2026)

Fri, 01 May 2026 15:00:00 GMT

Welcome to 2026 BioPacific Conference and thank you for sponsoring and exhibiting!

This is Step 1.

To become a sponsor or exhibitor of 2026 CABS BioPacific Conference, please follow the steps below:

1. Click the "Sponsor/Register" button at the right-corner and follow the step-by-step process to pay. The price will differ depends on level of sponsorship. Two payment methods:

A. Pay by credit card.

B. Pay by check. Click "invoice me" and then print out the invoice in your email. Mail the invoice together with the a check (payable to "CABS") to the following address: 268 Bush Street, #1888, San Francisco, CA 94104. U.S.A.

2. You will receive an email to confirm your payment. High level sponsors will get free guest conference admission passes. Please go to Step 2 to register yourself and free guests for conference admission.

Any question? Please contact: fundraising@cabsweb.org

Navigating Business Transactions and Deal-Making in Biotech (May 19, 2026)

Tue, 19 May 2026 23:30:00 GMT

Join us for an engaging evening of insights and connections at Navigating Business Transactions and Deal-Making in Biotech. This dynamic event brings together industry experts, innovators, and professionals to explore the critical elements of business transactions in the biotech space. Featuring a keynote session by K&L Gates, an inspiring fireside chat with entrepreneur Keting Chu on the journey behind Bluejay, and a thought-provoking panel discussion, the program offers valuable perspectives for anyone involved in biotech ventures. The evening concludes with a networking session—an excellent opportunity to connect, collaborate, and exchange ideas with peers and leaders in the field. Light refreshments and beverages will be provided.

Agenda:

4:30–5:00 pm: Check-in and Introduction

5:00–6:00 pm: Essentials in Business Transactions – by K&L Gates

6:00–6:45 pm: Fireside Chat with Keting: The Story of Bluejay

6:45–7:00 pm: Break

7:00–7:45 pm: Panel Discussion

7:45–8:30 pm: Networking

Speakers:

Keting Chu, MD. Ph.D

Founder, Chief Executive Officer and Chairman of the Board Bluejay Therapeutics, Inc.

Dr. Keting Chu is an experienced biotech executive, entrepreneur and life science venture inv estor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.

Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close $550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affimed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received “Breakthrough” designation by the FDA in 2016 after positive proof-of-concept studies. Celator was acquired by Jazz Pharma for $1.5B, Kite by Gilead for $12B and Stemline by Menarini for $677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therapeutic antibodies that keting led the team from discovery to phase I clinical trials went through phase II and III clinical testing.

Keting earned her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, and Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.

Linda Zhou, Partner, K&L

Linda Zhou has more than 20 years of experience in working with technology and biopharma companies and investors in venture capital and corporate transactions, including VC financings, M&As, licensing, joint ventures,and fund formations. Linda’s corporate representation includes work with many emerging companies as well as larger companies and VCs.

Linda works frequently on cross-border transactions. She has developed a robust practice guiding domestic clients in their outbound investment and assisting foreign companies in their inbound business expansion. She has acted as a trusted advisor for numerous technology companies and investors in complex acquisitions and global operations across key economic countries. Linda co-leads the firm’s Emerging Growth and Venture Capital practice. She is an experienced and well-known business lawyer in several local technology communities.

Linda obtained her Master of Laws in University of Wisconsin-Madison.

David Lu is a Chambers USA and LMG Life Sciences-recognized patent lawyer and a leader in intellectual property strategy and portfolio management. He is a partner in the firm's Intellectual Property practice, where he advises clients in the life sciences sector on patent prosecution, strategic IP portfolio development, and intellectual property due diligence related to mergers, acquisitions, licensing transactions, and investment activities. David has designed and implemented global patent strategies across the pharmaceutical and biotechnology industries and has managed high-impact portfolios for international enterprises, mid-sized biotechs, and venture-backed startups. He also provides patent landscape analysis, freedom-to-operate assessments, and patentability evaluations to support clients' innovation and commercialization efforts.

Prior to joining the firm, David served as a partner and co-lead of the life sciences group at a US-based law firm. Before transitioning into his legal profession, David conducted cancer research at the Dana-Farber Cancer Institute and Harvard Medical School, contributing to advancements in DNA damage response and BRCA1 biology, with emphasis on molecular mechanisms and microRNA-mediated regulation. His earlier academic work at Duke University focused on RNA biology and virology, exploring mRNA and viral microRNA biogenesis. David has authored numerous peer-reviewed publications in leading scientific journals and presented his research at renowned international conferences.

David obtained his J.D. from Suffolk University Law School (Intellectual Property Concentration with Distinction) and PhD from Duke University for Molecular Genetics and Microbiology.

Please scan the QR code to Register:

Translational AI in Biomedicine: From Discovery to Real-World Impact (May 30, 2026)

Sat, 30 May 2026 16:00:00 GMT

This workshop focuses on how artificial intelligence is transforming biomedical research and drug development. It brings together experts from academia and industry to explore how AI can accelerate discovery and improve the transition of scientific advances to real-world applications. The program highlights emerging AI approaches across the discovery-to-development spectrum and the practical considerations for applying them in life sciences. Ultimately, the workshop aims to encourage collaboration and generate new ideas for advancing AI-enabled biomedical innovation.

Workshop Agenda

Time	Title	Speakers
9:00 – 9:10 AM	Welcome Remarks from CABS	Sihong Zhou CABS President
9:10 – 9:20 AM	Introduction of the Workshop and Speakers	Alex Yang, CABS STC Co-chair, Vir Biotechnology
9:20 – 10:05 AM	Al Agents to AccelerateBiomedical Discoveries	James Zou, Associate Professor, Stanford
10:05 – 10:50 AM	TBD	Le Cong, Associate Professor, Stanford Charles Wu, AI researcher, Stanford
10:50 – 11:15 AM	Coffee Break
11:15 – 12:00 PM	Building the Life Science Super-Entrepreneur with AI: Engineering Commercialization Back to Discovery	Xi Fang, CEO of Innovo Health Labs
12:00 – 12:30 PM	TBD	Michelle Che, President and CEO of Form Bio
12:30 – 1:00 PM	Panel discussion and Closing Remarks	Lin Wang, CABS STC Co-chair, Gilead
1:00 – 2:30 PM	Lunch and Networking

Sponsor:

Innovo Health Labs

Announcing 2026 CABS K. Fong Award in Life Sciences (September 19, 2026)

Sat, 19 Sep 2026 15:00:00 GMT

Chinese American Bio/Pharmaceutical Society (CABS) Honors Dr. Randy Schekman and Dr. Joseph C. Wu with the 2026 K. Fong Award in Life Sciences

South San Francisco, CA - The Chinese American Bio/Pharmaceutical Society (CABS) proudly announces Dr. Randy Schekman, Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute, Nobel Prize Laureate and Dr. Joseph C. Wu, Director of Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology at Stanford Universityas the recipients of the prestigious 2026 CABS K. Fong Award in Life Sciences. Marking the 13th anniversary of this esteemed accolade, the award honors Dr. Schekman and Dr. Wu for their exceptional contributions to research, education, and translational innovation. The award will be presented at the 2026 BioPacific Conference on September 19, 2026, at the South San Francisco Conference Center.

Dr. Randy Schekman

Dr. Randy Schekman is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University. His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the University of California, San Diego. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof. He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, a Foreign Associate of the Accademia Nazionale dei Lincei, a Foreign Associate of the Royal Society of London and an Honorary Academician of the Academia Sinica. In 1999, he was elected President of the American Society for Cell Biology. From 2002-2017, he served as Editor-in-Chief of the Annual Reviews of Cell and Developmental Biology. From 2006 - 2011 he served as Editor-in-Chief of the Proceedings of the NAS. In 2011, he founded and until 2019 served as the Editor-in-Chief of the Open Access journal, eLife, sponsored by the HHMI, Wellcome Trust and the Max Planck Society. Beginning in 2019, Schekman became the scientific director of Aligning Science Across Parkinson’s, an effort supported by the Sergey Brin Family Foundation to identify and support basic research on the mechanisms of Parkinson’s Disease initiation and progression (https://parkinsonsroadmap.org).

Schekman’s laboratory investigates the mechanism of membrane protein traffic in the secretory pathway in eukaryotic cells. Currently the lab investigates the mechanism of biogenesis and function of extracellular vesicles and the unconventional secretion of alpha-synuclein as a potential means of the spread of brain pathology in Parkinson’s Disease.

Dr. Joseph C. Wu

Joseph C. Wu, MD, PhD is Director of Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology at Stanford University. Dr. Wu received his MD from Yale University and a PhD (Molecular & Medical Pharmacology) from University of California, Los Angeles. He is currently president of the Association of University Cardiologists (2026).

Dr. Wu’s research integrates genomics, stem cells/organoids, AI, and drug discovery. The main goals are to (i) understand fundamental disease mechanisms, (ii) advance precision medicine for patients, and (iii) accelerate drug discovery through “new alternative methodologies” (NAMs) and “clinical trial in a dish” (CTiD) concept. Dr. Wu has published >700 manuscripts with H-index of 151 on Google scholar. He has been listed among the top 0.1% of highly cited researchers by Web of Science for 8 consecutive years (2018-2025).

Dr. Wu has received several awards, including the NIH Director’s New Innovator Award, NIH Roadmap Transformative Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama at the White House, American Heart Association (AHA) Distinguished Scientist Award, AHA Merit Award, and Burroughs Wellcome Foundation Innovation in Regulatory Science Award. Dr. Wu previously served as President of the American Heart Association (2023-2024) and was on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee (2017-2025). He currently sits on the Boards of the Keystone Symposia, AHA, and Greenstone Biosciences (https://greenstonebio.com/), a startup that he co-founded which focuses on NAMs for drug discovery.

Dr. Wu is an elected member or fellow of the American Society for Clinical Investigation (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association of Physicians (AAP), Academia Sinica (Taiwan), American Association for the Advancement of Science (AAAS), Asian American Academy of Science and Engineering (AAASE), National Academy of Inventors (NAI), and National Academy of Medicine (NAM).

CABS is honored to recognize Dr. Schekman and Dr. Wu’s outstanding achievements, which have advanced the frontiers of science and contributed to improved human health. Their commitment to rigorous research, education, and innovation exemplifies the values of the K. Fong Award in Life Sciences.

For media inquiries and press registration for the award ceremony, please contact: info@cabsweb.org.

About CABS K. Fong Award in Life Sciences

The CABS K. Fong Award in Life Sciences is an esteemed annual recognition presented to individuals who have made exceptional contributions to the fields of life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates eligible for this award must be nominated by an active member of CABS. Selection criteria are based on candidate’s accomplishments in life sciences and contribution to the life science community, including one or all of the following:

Proven achievements in therapeutic breakthroughs (including discovery, process, or clinical development), diagnostics or research reagent/equipment markets.
Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
Significant contribution to the CABS community and promotion of international collaborations in life sciences.

The CABS K. Fong Award in Life Sciences aims to celebrate and honor exceptional individuals whose achievements and commitment have not only expanded the frontiers of life sciences but have also positively impacted global healthcare and well-being.

About Dr. Kenneth Fong

Dr. Kenneth Fong has spent the last 42 years in the biotech industry after completing his academic pursuit in biomedical research.

He is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was acquired by Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated 12 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 15 companies that are worth more than $7 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-2007) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-2013). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2003, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

Ken obtained his PhD from Indiana University and his post-doctoral studies at UCLA & NIH.

Past recipients of CABS K. Fong Awards

2025. Dr.Liqun Luo, Ann and Bill Swindells Professor of Biology at Stanford University, and Howard Hughes Medical Institute Investigator for his outstanding achievements, which have advanced the frontiers of brain science and contributed to improved human health.

2024: Dr. Zach Sweeney, Venture Partner at Versant Ventures, CEO and co-founder of Interline Therapeutics, CSO at Denali Therapeutics for his exceptional contributions and transformative impact on the pharmaceutical and biotechnology fields.

2023:Dr. Corey Goodman, Managing Partner at venBio, for his groundbreaking discoveries in neural development and axon guidance, as well as his visionary leadership in translating science into successful biopharmaceutical ventures that have significantly advanced human health.

2022: Dr. Scott Liu, Founder and CEO of HanchorBio, for his outstanding and pioneering contribution to the development of multiple biologic products from research to launch.

2021: Dr. John O. Link, Vice President of Gilead Sciences for his work on the drug discovery of Hepatitis C inhibitors and the HIV Capsid Inhibitor; and Dr. Xian-Ping Lu, Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD, for their extraordinary achievements in research, innovation and entrepreneurship.

2019: John V. Oyler, Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.

2018: Dr. Yuling Luo, Founder, CEO and Chairman of Alamar Biosciences (formerly the founder & CEO of Advanced Cell Diagnostics, ACD), and Dr. Guoliang Yu, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.

2017: Dr.Yinxiang Wang, Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana^®, the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China; and Dr. Edgar Engleman, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.

2016: Dr. Gerald Chan, Co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.

2015: Dr. Irving Weissman, Professor of Stanford University, for his pioneering work in stem cell research.

2014: Dr. Ge Li, Founder and CEO of Wuxi Apptec, for pioneering and shaping the CRO business model in China; and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and Iopinavir.

2013: Dr. Peter Hirth of Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market; and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.

Welcome to CABS 2026 BioPacific Conference (September 19, 2026)

Sat, 19 Sep 2026 15:00:00 GMT

Click Here To Register!

We are thrilled to announce that CABS will host the 2026 BioPacific Conference on September 19th, 2026, at the South San Francisco Conference Center, We look forward to welcoming you to this exciting conference！

Click the "Click here to register!" link to register on our Eventbrite page!

We are currently seeking additional sponsors to support this impactful event. If your organization is interested in partnering with us, please reach out via email at fundraising@cabsweb.org.

Registration Fees

Registration online as early as possible is highly recommended.

The registration on Sep 19, 2025 and on-site will be $250.

Category	Early Bird (by 8/31/2026)	9/1/2026 - 9/18/2026	Onsite 9/19/2026
CABS Member - General	80	120	250
CABS Member - Academic	50	70	250
Non-CABS Member - General	140	180	250
Non-CABS Member - Academic	110	130	250

Refreshments, lunch are included.

* Join CABS today ($60 for one year membership) to save on registration fee: http://www.cabsweb.org/members/

* Please contact info@cabsweb.org, if there are any questions about registration.

NOTE:

By registering for the CABS Biopacific Conference, you consent to the collection, use, and sharing of your personal information, including your name, contact details, and professional affiliation, for the purposes of conference communication and sharing with sponsors. This allows sponsors to follow up with you regarding their products, services, and opportunities. If you prefer not to have your information shared with sponsors, please indicate your preference (select "no" for the question [Would you like to share your email information with our sponsors?]) when you fill out your personal information before your checkout. We are committed to protecting your personal information in accordance with applicable data protection laws. By registering, you acknowledge that you have read, understood, and agree to these terms.